Cognitive enhancer

Cognitive enhancers, commonly known as nootropics, encompass a diverse group of pharmacological agents designed to boost cognitive processes such as memory formation, attention, executive function, and wakefulness in both healthy individuals and those with impairments. They primarily act by modulating key neurotransmitter systems—including cholinergic pathways via acetylcholinesterase inhibition (e.g., donepezil increasing acetylcholine for Alzheimer's symptom relief), dopaminergic and noradrenergic reuptake blockade (e.g., methylphenidate for ADHD), and glutamatergic/NMDA receptor potentiation (e.g., nefiracetam, piracetam enhancing synaptic plasticity)—or by promoting neuroprotection and membrane fluidity. In disease contexts, they target deficits in neurodegenerative conditions like Alzheimer's disease, where cholinergic decline predominates, and neuropsychiatric disorders such as schizophrenia or ADHD, often improving working memory and response inhibition through frontoparietal network effects. Drugs like modafinil promote wakefulness via hypocretin/dopamine mechanisms, while racetams like piracetam support neuroplasticity without direct receptor binding. Therapeutically, approved agents like donepezil and methylphenidate offer symptomatic relief, but many pipeline candidates (e.g., α7 nicotinic agonists) aim for disease modification amid challenges like peripheral side effects and waning efficacy. Overall, while promising for cognitive restoration, their translation to broad enhancement in healthy users remains inconsistent and debated.

Other names

nootropicsmart drugmemory enhancerconcentration enhancerneuro enhancerintelligence enhancer

Dopamine/noradrenaline reuptake inhibition, cholinesterase inhibition (increasing acetylcholine), nicotinic acetylcholine receptor agonism (e.g., α4β2, α7), NMDA receptor potentiation, phosphodiesterase inhibition, modulation of membrane fluidity/neuroplasticity